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Inherited myopathies affect both skeletal and cardiac muscle and are commonly
associated with genetic dysfunctions, leading to the production of anomalous proteins. In
cardiomyopathies, mutations frequently occur in sarcomeric genes, but the cause-effect
scenario between genetic alterations and pathological processes remains elusive.
Hypertrophic cardiomyopathy (HCM) was the first cardiac disease associated with a
genetic background. Since the discovery of the first mutation in the β-myosin heavy chain,
more than 1400 new mutations in 11 sarcomeric genes have been reported, awarding
HCM the title of the “disease of the sarcomere.” The most common macroscopic
phenotypes are left ventricle and interventricular septal thickening, but because the
clinical profile of this disease is quite heterogeneous, these phenotypes are not
suitable for an accurate diagnosis. The development of genomic approaches for clinical
investigation allows for diagnostic progress and understanding at the molecular level.
Meanwhile, the lack of accurate in vivo models to better comprehend the cellular events
triggered by this pathology has become a challenge. Notwithstanding, the imbalance
of Ca2+ concentrations, altered signaling pathways, induction of apoptotic factors, and
heart remodeling leading to abnormal anatomy have already been reported. Of note, a
misbalance of signaling biomolecules, such as kinases and tumor suppressors (e.g., Akt
and p53), seems to participate in apoptotic and fibrotic events. In HCM, structural and
cellular information about defective sarcomeric proteins and their altered interactome is
emerging but still represents a bottleneck for developing new concepts in basic research
and for future therapeutic interventions. This review focuses on the structural and cellular
alterations triggered by HCM-causing mutations in troponin and tropomyosin proteins
and how structural biology can aid in the discovery of new platforms for therapeutics. We
highlight the importance of a better understanding of allosteric communications within
these thin-filament proteins to decipher the HCM pathological state.
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INTRODUCTION
Cardiomyopathies represent a collection of disorders that
originate in the heart muscle itself or as a side effect of
some other systemic conditions, leading to heart damage and
electrical function impairment (Maron et al., 2006). According
to the American Heart Association (AHA), cardiomyopathies
are classified into two major groups: primary, referring to
those predominantly affecting the heart muscle, and secondary,
referring to those with the pathological involvement of the heart
in a large number of systemic diseases (Maron et al., 2006).
Hypertrophic cardiomyopathy (HCM) is a primary muscle
disease and the most common cause of sudden cardiovascular
death in young athletes; however, cardiovascular death caused
by HCM is 8 times more frequent when considering not only
young athletes. The same pattern is true for the incidence of
HCM, which is 3 times higher in the young population (Maron
et al., 2016a). Of note, HCM affects 1 in 500 individuals in the
general population, but this ratio may be underestimated due to
the lack of information regarding familial cases or asymptomatic
subjects (Mozaffarian et al., 2016). HCM was the first cardiac
disease associated with a genetic background and presents an
autosomal dominant pattern of inheritance. Sequencing efforts
have allowed the discovery of the first HCM-causing mutation
in the β-myosin heavy chain (MHY7 gene, R403Q) (Geisterfer-
Lowrance et al., 1990). Since then, more than 1400 mutations in
11 sarcomeric genes have been unveiled, and due to this pattern
of affected genes, HCM is also called the disease of the sarcomere
(Watkins et al., 1992, 1995; Thierfelder et al., 1994; Seidman and
Seidman, 2001; Konno et al., 2010).
The clinical profile of HCM is quite heterogeneous. While
some patients exhibit severe to mild manifestations, others are
completely unaware of having the disease. The initial suspicious
of HCM come from a heart murmur during physical activity,
family history, or an abnormal echocardiogram (ECG) pattern
(Marian, 2010; Maron et al., 2012; Maron and Maron, 2013).
Its diagnosis is based on two-dimensional echocardiography,
which permits the detection of an asymmetric hypertrophied
left ventricle chamber. Of note, the HCM diagnose should be
taken in the absence of other diseases with similar clinical
profiles (e.g., aortic stenosis or hypertension) (Maron et al.,
2014, 2016b). Moreover, other HCM clinical manifestations
include left ventricular hypercontractility, cardiac insufficiency,
ventricular fibrillation, syncope and arrhythmias. Regarding its
morphological and histological features, left ventricle wall and
ventricular septum thickening typically occurs (Teare, 1958;
Maron et al., 1979; Varnava et al., 2001). The architecture of
the hypertrophic myocardial fibers differs in shape and angle
arrangement, leading to a chaotic environment (Maron et al.,
1981). In combination with cellular disarray, fibrosis with an
abnormal collagen matrix is also observed (St. John Sutton
et al., 1980; Shirani et al., 2000; Kwon et al., 2009; Nakamura
et al., 2016). Indeed, a possible clinical correlation between
these findings and HCM pathology impairs the proper relaxation
of the heart, preventing it from filling correctly. Damage
to the electrical signal conduction may also occur, leading
to arrhythmia, tachycardia and ventricular fibrillation, which
may ultimately contribute to the development of secondary
pathologies, e.g., ischemia or hypotension (Kon-No et al., 2001;
Christiaans et al., 2009; Lan et al., 2013; Crocini et al., 2016).
Altered ion channels including at least six susceptible genes, e.g.,
KVLQT1, HERG, SCN5A, minK, MiRP1, and RyR2 play critical
steps during the development of arrhythmia phenotypes (Keating
and Sanguinetti, 2001). Of note, the ryanodine channel (RyR2)
triggers the release of Ca2+ from the sarcoplasmic reticulum
to start contraction. Mutations in RyR2 lead to aberrant
intracellular Ca2+ metabolism and Ca2+ overload that may have
an involvement in arrhythmias (Keating and Sanguinetti, 2001).
Additionally, during the phase 0 depolarization of the cardiac
action potential, the binding of calmodulin to the C-terminal
region of the hH1 Na+ channel occurs in a Ca2+-dependent
manner and impact the slow inactivation gating process with
implications to cardiac arrhythmias (Tan et al., 2002). Because
the HCM clinical phenotype ranges from asymptomatic subjects
to patients who require surgery or transplant, it is reasonable
to use both clinical data and imaging tests during initial
screening, but this may not be the most effective approach
for the diagnosis probands carrying a silent disease. Genetic
tests are available for molecular diagnosis, to identify HCM-
causing mutations of the proband and for family screening (Ho
et al., 2015). These trials were conducted at the bench and
were breakthroughs, promoting a fast and reliable diagnosis
(Maron et al., 2012). However, despite all efforts in the molecular
biology field, the association between mutational profile and
disease phenotype remains elusive. For instance, one interesting
question is why some mutations trigger a pathogenic status
while others lead to a benign course. The most parsimonious
explanation is that mutations not only affect protein function but
may also cause changes in folding, dynamics and interactomes.
In this review, we focused on recent discussions of the
structural basis for the effects and cellular consequences of HCM
mutations.
FROM CODE TO MESSAGE
Almost 50 years ago, Francis Crick published a noteworthy article
entitled the “Central dogma of molecular biology” (Crick, 1970).
At that time, it was postulated that in the cellular environment,
the flow of information initiates through the deoxyribonucleic
acid (DNA) molecule that contains all of the elements for protein
production. The intermediate molecule responsible for carrying
a copy of the target protein is called ribonucleic acid (RNA).
Finally, this template requires a complex cellular machinery for
protein synthesis.
Drawing a parallel between the central dogma of molecular
biology and the theory of communication (Figure 1), five key
elements should be considered for successful communication.
(i) The source of information is important for producing the
message. An analogy of the source could be a sequence of letters
organized in a coherent way to form a word or sentence. (ii)
The transmitter is responsible for sending this message through
a channel. (iii) The channel links the transmitter to the receiver.
(iv) The receivermakes the message intelligible when reaching its
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FIGURE 1 | The theory of communication in biology. Schematic representation highlighting the key elements for correct communication in biology. DNA is the
source of information and carries the correct message to produce a functional protein. RNA molecules link the source to the channel. The nuclear pore complex (NPC)
serves as a selective channel and sends the RNA to the receiver. The ribosome is the first receiver responsible for making the message intelligible (translate from RNA
to protein). Additional receivers, including the endoplasmatic reticulum (ER) and the Golgi apparatus, will help the protein to achieve its proper folding and
post-translational modification to reach the final destination and correct response.
destination. (v) The destination is where the message arrives and
can then perform its function (Shannon, 1948).
Considering the polypeptide chain of a hypothetical protein
as a message to be sent, the specific DNA region that carries
the correct nucleotide sequence for this protein (i.e., the gene)
serves as the source of information. Equally important, the RNA
molecule plays the transmitter role, allowing the correct message
to reach the channel. The nuclear pore complex recognizes
mature RNA molecules and sends them to the receiver, thus
serving as a selective channel. Next, the complex machinery
of the ribosome acts as the receiver, transforming the genetic
information through the synthesis of a correct polypeptide
sequence. In this analogy, additional receivers would allow
proper polypeptide folding (e.g., the endoplasmatic reticulum
and chaperone molecules) and the incorporation of important
modifications, such as phosphorylation and glycosylation, among
others (e.g., kinase proteins and the Golgi apparatus). Finally,
the destination of this functional protein will generate the
expected response inside or outside the cell. This simplistic
analogy illustrates how any substitution occurring at the message
level may significantly affect the correct communication and
cause either a misunderstanding or a new understanding at the
destination (Figure 1).
Correct folding is intimately linked to the function or,
analogously, the message of a biomolecule. A remarkable study
in the 1950s showed that the three-dimensional assembly of
a protein is guided by its specific amino acid sequence. The
physicochemical properties of specific amino acid side chains
lead to a hydrophobic collapse event; thus, proper folding is
expected to occur independently of biological cellular machinery
(Anfinsen et al., 1961; Anfinsen, 1973). The energy landscape is
an accepted theory to explain the protein folding phenomenon
(Onuchic et al., 1997). Proteins normally experience a wide
range of conformational changes to reach their low-energy native
state. In terms of free energy, folding pathways are commonly
summarized using schematic funnels, in which high-energy
protein stages (i.e., denatured polypeptides) are guided through
preferential intramolecular contacts to achieve the lowest free
energy and conformational entropy (i.e., native polypeptides).
The folding of a single polypeptide chain, therefore, occurs
through the assembly of partially folded intermediates due to
dynamics and, together with water solvation, plays an essential
role in this process (Bai and Englander, 1996; Dill and Chan,
1997; Onuchic, 1997; Cheung et al., 2002; Onuchic andWolynes,
2004; Dill et al., 2007).
The assembly of tightly bound or transiently bound molecular
complexes in the perspective of energetic landscapes requires
an orchestrated and hierarchic environment in which a
range of molecular motions take place (Figure 2). Polypeptide
chains are intrinsically dynamic entities sampling different
conformations from pico- to millisecond timescales during
folding and upon activation or molecular recognition. Rapid
fluctuations (i.e., thermal motions on the order of 10−12–
10−9 s) commonly occur in native globular proteins and
result in structurally similar conformers with implications for
molecular recognition (Figure 2A). At the opposite side of
the energetic landscape, intrinsically disordered proteins (IDPs)
are very flexible molecular motors, sampling heterogeneous
conformations with high free energy and conformational
entropy (Figure 2B). In both scenarios, we may exemplify
slower timescale dynamics (i.e., on the order of 10−6–
10−3 s) in which a small number of high-energy and short-
lived conformers are populated (Figure 2C). This condition is
normally observed in more complex proteins with intrinsically
disordered regions (IDRs), such as flexible linkers or hinge-
connecting domains, and that participate in relevant biological
processes, including molecular assemblies, catalysis and ion-
coordination. In the context of multi-domain proteins (i.e.,
globular domains linked by IDRs) and the broad spectrum
of motions that arise from these complexes (Figure 2D), an
understanding of how hierarchical motions trigger the formation
of tightly or transiently bound molecular assemblies and
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FIGURE 2 | Energetic landscapes. Schematic representing the minimization of conformational entropy (S) and free energy (G) during the folding of (A) globular
proteins, (B) intrinsically disordered proteins (IDPs), and (C) multi-domain proteins. In (C), two different conformations, a and b, triggered by linker motions, are
represented. (D) Molecular recognition and assembly landscapes for the cTn complex formed by cTnC, cTnI, and cTnT (PDB code 1j1e). During molecular
recognition, higher-energy sub-states are formed to guarantee the correct sampling among the different biological partners.
the physiological and pathological consequences is just now
emerging.
The consequences of alterations in the DNA can be compared
to “heaven or hell.” Evolutionary events are commonly beneficial
in which adaptive species and precise protein functionalities are
selected butmay also be catastrophic when loss-of-function (LoF)
or gain-of-function (GoF) events occur. Upon mutation, LoF
and GoF events are commonly observed in different proteins,
including tumor suppressors and sarcomeric proteins, with
implications in cancer and cardiac disorders (Marston et al., 2013;
Silva et al., 2014). Several organisms have developed specialized
repair machineries to address DNA variations and avoid disease,
but this is not an infallible process. In addition, the evolution of
polypeptide chains does not always result in the correct alphabet
sequence (Goldschmidt et al., 2010; Eichner and Radford, 2011).
The consequence is that protein misfolding is attributed to more
than 50 diseases (Chiti and Dobson, 2006). DNA alterations
can change the phenotype with positive, negative or neutral
consequences to the adaptability of individuals. The production
of faulty proteins causes functional impairment, which may alter
contacts with molecular partners, leading to dramatic cellular
responses. Among the main variations observed in the DNA,
one type can be highlighted in the context of cardiomyopathies:
single point mutations. Approximately 90% of these pathogenic
mutations are missense, in which one amino acid is changed to
another, leading to abnormal molecular, functional and physical
properties of the heart.
Pathogenic mutations have at least two important features: (i)
they lead to alterations in protein structure and function and
(ii) changes frequently occur in highly conserved amino acids
throughout evolution (Richards et al., 2008; Maron et al., 2012).
In HCM, these two features are observed, and one mutation
affecting a conserved region can disrupt pivotal protein-
protein interactions, leading to structural chaos. Interestingly,
because only key amino acids contribute to the free energy of
binding, interaction sites frequently display an asymmetrically
energy distribution along the surface. The presence of highly
conserved amino acids surrounding the interaction interface
plays a key role in stabilizing molecular contacts. Accordingly,
complementary pockets comprising bulky side chains tightly
stabilize the interaction in a geometrically and energetically
favorable manner (Keskin et al., 2005; Metz et al., 2012). When
dealing with protein-protein interactions, in addition to size
and chemical complementarities, conformational fluctuations
in different timescales also take place for proper binding and
signaling (Henzler-Wildman and Kern, 2007; Zen et al., 2010).
Mutations in highly conserved regions frequently result in steric
impairment and conformational changes with LoF or GoF events.
Thus, protein dynamics are highly relevant when considering the
investigation of protein-protein interactions in physiological and
pathological processes.
With regard to RNAmodifications impacting cardiomyopathy
phenotypes, much attention are being taken to non-conding
RNAs (e.g., microRNAs—miRNA) and the process of alternative
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cleavage and polyadenylation (APA) of mRNAs as regulators
of gene expression. For instance, downregulation of a specific
miRNA locus in stressed cardiomyocytes is sufficient to
attenuate the increase of cell size (Clark et al., 2016) and the
levels of miR-499 are increased in failing and hypertrophied
hearts with consequences to the levels of target mRNAs.
Proteomic analysis linked to miR-499 identified changes in
kinase and phosphatase signaling, supporting the key role of
these non-conding RNAs in the pathological regulation of
cardiomyopathies (Matkovich et al., 2012). Of note, the secretion
of miR-29a in the plasma of HCM subjects is associated to
both hypertrophy and fibrosis and may serve as a potential
biomarker in HCM supporting a direct role of miRNAs in
the HCM pathogenesis (Roncarati et al., 2014). Additionally,
the APA process of mRNAs is particularly important to
generate RNA isoforms and modulate the levels of protein
expression in specific genes. In dilated cardiomyopathy a group
of genes involved in RNA and actin binding and structural
proteins of the cytoskeleton revealed a different profile of
mRNA cleavage and polyadenylation and it may account for an
additional level of regulation in failing hearts (Creemers et al.,
2016).
The bottleneck in our current understanding is the assessment
of dynamic changes arising from mutational events in well-
organized assemblies, such as the sarcomere, and defects
generating pathogenic profiles. More interesting, different
mutations in diverse targets can culminate in the same disease
but sometimes with distinct phenotypes.
THE SARCOMERE
To better understand the complexity of the sarcomere, it is
important to address some important structural features about
this system (Clark et al., 2002; Gautel and Djinovic´-Carugo,
2016). The sarcomere is a basic contractile unit that repeats
regularly throughout myofibrils (Huxley and Niedergerke, 1954)
being the responsible for the transformation of chemical energy
into mechanical energy, thereby triggering contraction (Bers,
2001). To execute this task, the architecture of the sarcomere is
finely orchestrated. Through electron microscopy visualization,
several elements can be identified including the Z-discs, M
lines, A bands, and H zones. The borders of a sarcomere
unit are defined by Z-discs and are the places where the
thin filaments, titin and nebulin are anchored. These discs
are also involved in mechanosensitivity and nuclear signaling,
which contribute to the maintenance of muscle homeostasis
(Clark et al., 2002). Of note, the giant titin protein has
received much attention with regard to its potential role
in the passive and residual force enhancement (Herzog and
Leonard, 2002). Stretching active and passive myofibrils to
a length that avoided any force contributions from actin-
myosin cross-bridges revealed greater force generation in actively
when comparing to passively stretched myofibrils, supporting
the involvement of titin molecules on this force generation
mechanism (Leonard and Herzog, 2010). A three-filament model
of force production emerged from these findings with the
participation of Ca2+ and actin binding to titin molecules
(Herzog et al., 2016 and references therein). For more in-depth
information on the advantages and limitations of the actin-
myosin-titin communication for force generation (three-filament
model) with respect to the classical view of cross-bridge, please
refer to specialized literature (Herzog et al., 2016; Li et al.,
2016).
The M line is the transverse structure located in the center
of the sarcomere and has been proposed to be the anchor site
of the thick filament through the formation of cross-bridges
(Obermann et al., 1996; Agarkova et al., 2003). Toward the center
of the sarcomere is the A band composed of thick filaments
and associated proteins, e.g., the myosin-binding protein C.
This protein plays an important role in regulating myosin
polymerization and aligning the thick filaments within the A
band. Within this region, a whiteness segment called H is also
observed and consists of thin filaments that do not overlap into
thick filaments (Clark et al., 2002). The thick filaments are mainly
composed of myosin which has three functional domains: the
head, the neck, and the tail (Sellers, 2000). The head is the
motor domain binding ATP and actin, while the neck region
binds to its light chains or calmodulin. Finally, the myosin
tail anchors and moves the motor domain toward an efficient
interaction with actin (Saez et al., 1987; Sellers, 2000). Six
subunits promote a hexameric three-dimensional architecture
that includes two heavy chains (myosin heavy chain, MHC) and
four light chains (myosin light chain, MLC). The MLC is divided
in two domains with regulatory functions and another two
domains with structural functions. Together, they finely adjust
the motor activity of myosin and the versatility of its kinetics
(Milligan, 1996).
The thin filament is the major Ca2+ regulation site and
comprises actin, tropomyosin (Tm) and the troponin complex
(Tn). Actin is a ubiquitously expressed protein and participates
in various cellular events, such as motility, cytokinesis and
contraction. Although some actin mutations are involved in
the HCM (Bai et al., 2015), we will focus this review on the
Tn and Tm mutations. Along the length of monomeric actin
resides Tm, a “coiled-coil” dimer that interacts in a “head-
tail” manner to form a substantial and almost uninterrupted
structure around the actin helices. One “coiled” motif interacts
with seven actin monomers via saline ionic interactions or
throughMg2+, and its main function is to inhibit myosin ATPase
activity in the absence of Ca2+ (Zot and Potter, 1987). The
cardiac Tn (cTn) complex is composed of three subunits (C, I,
and T) with different three-dimensional structures and functions.
Together, these subunits perform the important role of Ca2+ and
contraction regulation. Cardiac troponin C (cTnC) is the direct
Ca2+ sensor in the myofilament. The conformational changes
triggered by Ca2+ binding at specific cTnC sites control the
allosteric signaling cascade along the entire complex. Cardiac
troponin I (cTnI) performs the classical role of ATPase activity
inhibition. In addition, its tridimensional structure plays an
important regulatory role in protein-protein interactions. The
cardiac troponin T (cTnT) is the “molecular glue” that anchors
the Tnmembers to the thin filament, playing an important role in
Ca2+ transduction structural signaling. Together, the Tn complex
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and Tm represent the regulatory proteins of the thin filament
(Zot and Potter, 1987).
THE THIN FILAMENT REGULATORS
The cardiac contraction-relaxation cycle is a physiological
event controlled by electric and neurohormonal factors.
At the molecular level, this process requires sophisticated
protein machinery, i.e., the sarcomere, to manage both chemical
and mechanical processes. Particularly interesting, this exquisite
machinery exhibits an extensive intra- and intermolecular
network. In this context, fine-tuned protein-protein interactions
are essential for the correct contraction-relaxation operation.
The Tn complex and Tm are the key macromolecules responsible
for the modulation of both dynamics and structural signaling
along the myofilament. As will be discussed further, these
proteins ultimately regulate the exposure of the myosin-actin
binding sites.
TROPONIN I
cTnI is the inhibitory unit of the Tn complex and plays
an important role as a structural regulator of actomyosin
ATPase activity (Leavis and Gergely, 1984). During a heartbeat,
cTnI participates in the systolic/diastolic cycle upon changes
in the intracellular Ca2+ concentration. Using a series of C-
terminal mutations, the regulatory segments of TnI involved
in the anchoring of TnC to the thin filament start to be
addressed (Ramos, 1999). Currently, cTnI can be divided into
six different functional regions (Li et al., 2004): (i) an N-terminal
extension region (residues 1–30) containing two PKA-dependent
phosphorylation sites (Ser23 and Ser24) (Robertson et al., 1982;
Chandra et al., 1997); (ii) an N-terminal region (residues 34–71)
that interacts with the cTnC C-domain, playing a structural role
(Gasmi-Seabrook et al., 1999; Mercier et al., 2000); (iii) a region
that binds to cTnT (residues 80–136) as part of the IT-arm; (iv)
an inhibitory region (TnI128−147) containing a highly conserved
amino acid sequence among TnI isoforms; (v) a switch region
(cTnI147−163) that experiences a disordered-ordered transition
upon binding to the N-terminal domain of cTnC-triggering
contraction (Li et al., 1999); and (vi) the C-terminal region
(residues 164–210) serving as a second consensus site that binds
to actin and Tm (Solaro, 2010; Figure 3). Upon β-adrenergic
stimulus, two PKA-dependent phosphorylation sites (Ser23/24)
within the N-terminal segment of cTnI become phosphorylated
and play important roles in the Ca2+ desensitization activity
of the myofilament, culminating in heart relaxation (Zhang
et al., 1995; Solaro et al., 2013). Additionally, other residues
in cTnI, including Ser43/45 and Thr143, were shown to be
phosphorylated by PKC (Noland et al., 1995), with physiological
and pathological implications (Solaro et al., 2013). These N-
terminal residues of cardiac TnI are absent in fast and slow TnI
isoforms, providing an additional key regulatory segment for
the cardiac tissue. At the central region of cTnI, the inhibitory
segment (residues 128–147) was shown to attach to actin in the
absence of Ca2+ but shifts toward an interaction with cTnC
upon Ca2+ addition (Potter and Gergely, 1974; Kobayashi et al.,
1999).
In fact, cTnI is an important molecular switch during the
systolic/diastolic cycle. During diastole, low levels of Ca2+
stabilize a cTnI conformation that suppresses the power stroke
and thus prevents actin-myosin interactions, mostly because the
cTnI inhibitory region is sitting on actin (Solaro, 2010). During
β-adrenergic stimulation, the intracellular Ca2+ concentration
increases from a diastolic level of 100 nmol/L to a systolic level of
1mmol/L, enabling contraction (Bers, 2000). The affinity of cTnI
to actin is reduced upon the binding of Ca2+ to the N-terminal
domain of cTnC (cNTnC), releasing actin inhibition (Solaro and
Rarick, 1998). The cTnI inhibitory region now interacts in close
proximity to the D/E linker in the cTnC (Lindhout and Sykes,
2003), and the cTnI switch region moves toward the exposed
hydrophobic patch in the cNTnC, stabilizing its open (and
active) conformation. This mechanism causes cTnI to serve as
a molecular latch mediating actin exposure in a Ca2+-dependent
manner to trigger or inhibit contraction.
Due to the important regulatory role of cTnI in the thin
filament, mutations that affect cTn structural cooperativity can
lead to the development of diseases. Because several studies have
attempted to characterize and better understand the functional
defects of cTn mutations in the HCM phenotype, our main focus
here is to provide an overview of groundbreaking works and
recent literature; unfortunately, we cannot provide a complete
review of this vast and enthusiastic literature. Please, for
additional studies, see the references cited therein.
The majority of cTnI mutations associated with the HCM
phenotype are located in the C-terminal region (Figure 3).
Kimura and coworkers reported the first six mutations (R145G,
R145Q, R162W, 1K183, G203S, and K206Q), and almost 30
variations have been reported so far (Kimura et al., 1997; Willott
et al., 2010). Interestingly, almost 60% of the HCM-causing
cTnI mutations occur through the substitution of a positively
or negatively charged amino acid for a neutral or hydrophobic
one. Of note, arginine replacement occurs ∼40% of the time
(Willott et al., 2010). Most of the functional defects triggered
by these mutations were explored using skinned cardiac muscle
fibers. For example, all of these mutants except for G203S had
increased Ca2+ sensitivity of myofibrillar ATPase activity and
force generation (Takahashi-Yanaga et al., 2001a). As expected,
both mutations at position 145 comprising the inhibitory
consensus site presented decreased inhibitory cTnI activity, in
contrast to R162W and 1K183, which presented decreased
affinity for the cTnI-actin interaction. With the exception of
R162W, none of the other mutations perturbed the cTnI-
cTnC interaction (Takahashi-Yanaga et al., 2001a). Using surface
plasmon resonance, R162W revealed higher affinity for cTnC in
the presence of Ca2+ (Elliott et al., 2000). Further investigations
have explained how R145G impacts the cTnI inhibitory activity.
Using skinned cardiac fibers, the authors revealed that this
mutation impairs force development and muscle relaxation,
possibly explaining some of the clinical features of HCM (Lang
et al., 2002). Interestingly, cTnI mutations located at the second
actin-Tm-binding site (D190H and R192H) did not increase
the levels of ATPase activity, in contrast to the previous R145G
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FIGURE 3 | The hypertrophic cardiomyopathy mutations in the troponin complex. (A) Schematic representation of the cTnI, cTnC, and cTnT sequences. The
TnI and TnT contact sites are depicted in horizontal arrows. Red arrows highlight HCM-causing mutations in cTn subunits in accordance with Willott et al. (2010).
Yellow spheres represent cTnI phosphorylation sites. (B) Crystal structure of the Tn complex (PDB code 1j1e) and isolated subunits cTnI (green), cTnT (blue), and
cTnC (red), highlighting some residues (yellow sticks) affected by HCM-related mutations. The green spheres in cTnC represent Ca2+, and the black dashed line
represents the inhibitory peptide sequence of cTnI. Note, position 84 in cTnC (PDB code 1j1e) is serine instead of cysteine.
mutation located at the cTnI inhibitory segment (Kobayashi
and Solaro, 2006). Pathogenic mutations occur at different
regulatory segments of cTnI (for the cTnI mutation involved in
cardiomyopathies, please Willott et al., 2010). This observation
provides insights into the potential repertoire of functional
defects that cTnI would be involved. Because cTnI is involved
in a series of complex interactions with different biological
partners in the thin filament, the expectation is that different
cTnI mutation sites will trigger distinct functional defects, as
clearly observed in the literature. Although the literature is well
designed and ongoing, the explanation of how each of these
mutations reflects the clinical HCM phenotypes seems to be
challenging.
The development of transgenic animal models represents a
serendipitous way to associate mutational defects with disease
phenotypes. For example, transgenic mice carrying cTnI R146G
(R145G in humans) presented cardiomyocyte disarray, fibrosis,
and hypercontractility with diastolic dysfunction, symptoms
that align with an increased sensitivity to Ca2+ and the HCM
phenotype (James et al., 2000). In contrast, a slight decrease
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in the Ca2+ sensitivity of force development was also reported
for these cTnI R146G mice (Kruger et al., 2005). In an
elegant study, Wen and coauthors were able to study using
R245G transgenic mice concomitant measurements of force and
actomyosin ATPase activity in skinned papillary fibers to extract
the rate of cross-bridge turnover and energy cost. Compared
to fibers from a human cTnI wt mice, the fibers from the
R245G mice decreased the average force per cross-bridge and
revealed a higher energy expenditure, suggesting that in the
HCM phenotype, compensatory mechanisms may take place in
the heart of R145G mice (Wen et al., 2008). More recently,
molecular dynamic (MD) simulations using the whole cTn
complex incorporated with cTnI-wt, cTnI-R145G and the cTnI-
R145G/S23D/S24D phosphomimetics provided atomistic details
to explain new interactions between cNTnC (residues 1–89)
and cNTnI (residues 1–41) and the effects of R145G on these
interactions (Lindert et al., 2015). The incorporation of aspartic
acid substitutions at the PKA-dependent phosphorylation sites
of cTnI was validated to recapitulate the same contractile
properties and Tn function as does PKA (Lindert et al., 2015
and references therein). The MD simulations revealed that in
the cTn complex incorporated with the wt cTnI containing the
S23D/S24D phosphomimetics, the loss of contact between cNTnI
region 1–41 and the A and B helices of cNTnC occur because
of the repositioning of the cNTnI region to interact with the
cTnI inhibitory peptide due to phosphorylation. Accordingly,
this disordered N-terminal segment of cTnI was previously
shown to interact with the cNTnC in the unphosphorylated
state, thereby stabilizing for cNTnC a rigid and open orientation
(Ferrières et al., 2000). Additionally, this interaction was
disrupted by the phosphorylation of Ser23/24 during the β-
adrenergic stimulus to induce a lusitropic condition. More
interesting, when the R145G cTnI inhibitory peptide mutant was
incorporated for theMD simulations, the cNTnI1–41-cTnI128–147
interaction did not occur, and this extreme N-terminal region
of cTnI maintained contact with the cNTnC region regardless
of the presence of phosphomimetic mutations. In the same
line, the R146G (R145G in human) and R21C cTnI mutants
altered the PKA-dependent effects on weakening cTnC-cTnI
interactions and accelerating myofibril relaxation (Cheng et al.,
2015). These observations explain how R145G reduces the
modulation of the cTn complex by S23/24 phosphorylation
upon β-adrenergic stimulus and adds evidence for intramolecular
contact in cTnI triggered by phosphorylation (Lindert et al.,
2015).
The C-terminal end segment of cTnI is the most conserved
structure among the cTnI isoform and species and is the site of
the G203S and K206Q mutations. This region presents several
charged amino acids and a highly flexible structure and seems
to interact with Tm, playing a role in the Ca2+ switch of the
thin filament (Sheng and Jin, 2014). Both mutants affect the
backbone structure of cTnI; in particular, K206Q increases the
maximum levels of ATPase activity and the filament sliding
velocity (Deng et al., 2003; Köhler et al., 2003). Moreover, G203S
disrupts the interaction between cTnT and cTnC, resulting in
Ca2+ deregulation. Transgenic mice expressing the cTnI mutant
G203S revealed a faster inactivation rate of the L-type Ca2+
channels and a greater increase in the mitochondrial membrane
potential and metabolic activity upon activation compared to wt
myocytes (Tsoutsman et al., 2006; Viola et al., 2016).
Remarkably, there is only one identified mutation in
the N-terminal region of cTnI so far: the R21C mutant
(Gomes et al., 2005). This mutation is located within the
consensus phosphorylation site of PKA. In vitro studies
demonstrated that R21C increases the Ca2+ sensitivity but
reduced the phosphorylation levels when incubated with PKA.
The physiological effect of PKA on decreasing the Ca2+
sensitivity of force development was diminished in cTnI
R21C (Gomes et al., 2005). Additionally, the generation of
R21C knock-in mice revealed the interesting behavior of this
intriguing mutant. Top-down electron capture dissociation
mass spectrometry revealed that R21C indeed depleted the
phosphorylation status of S23/S24 cTnI in R21C homozygous
(+/+) mice and decreased it by 8% in R21C heterozygous (+/−)
mice compared to wt mice, supporting R21 as a crucial residue
for PKA recognition and subsequent phosphorylation (Wang
et al., 2012). Additionally, heterozygous R21C mice incorporated
∼25% of R21C to the thin filament. The development of an
HCM phenotype with cardiac hypertrophy, fibrosis, and the
activation of the fetal gene program in both +/+ and+/− R21C
mice supports a negative-dominant effect of this pathogenic
mutant to the wt cTnI that is intensified to diastolic dysfunction
and excitation-contraction uncoupling upon long-term ablation
of cTnI phosphorylation (Dweck et al., 2014). Of note, these
mice (+/+) also presented distinct contractile forces when
comparing left and right ventricles (Liang et al., 2015). Curiously,
the use of post-mortem heart tissues revealed ∼56 and 1%
cTnI phosphorylation when comparing normal and affected
patients, respectively. Thus, mapping cTnI phosphorylation
levels presents a promising biomarker for the early detection of
hypertrophy (Zhang et al., 2011).
TROPONIN T
cTnT is the subunit responsible for anchoring the cTnC and
the cTnI to the thin filament and serves as an important
communication switch in transferring the conformational
changes induced by Ca2+ over the cTn complex and Tm (Leavis
and Gergely, 1984; Tobacman, 1996). Due to genetic shuﬄing,
several TnT isoforms are expressed across species, cell types
and within the cellular environment (Anderson et al., 1991;
Perry, 1998). The main structural difference between cardiac
and skeletal TnT is the length of the N-terminal domain
segment. This region carries the major structural multiplicities
that are generated by genetic shuﬄing and is known as the
hypervariable region. During heart development, an alternative
splicing of exons 4 and 5 gives rise to different variants in
size, physicochemical features and, thus, functions and Ca2+
responsiveness (Anderson et al., 1991; McAuliffe and Robbins,
1991). Four TnT isoforms can be detected in the heart: TnT1 (all
exons), TnT2 (exon 4 is spliced out), TnT3 (exon 5 is spliced
out), and TnT4 (exons 4 and 5 are spliced out) (Gomes et al.,
2002). Due to this arrangement, the TnT molecular weight varies
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from 31 to 36 kDa, presenting 250–300 amino acid residues
(Perry, 1998). In addition, altered patterns of cTnT expression
were observed in heart failure and hypertrophy. Protein levels are
directly associated with disease severity, suggesting an important
role in the pathological state (Anderson et al., 1991, 1995;
Townsend et al., 1995; Saba et al., 1996). The TnT is classically
divided in two domains, T1 and T2, based on observations
by Ohtsuki (1979). The proteolytic cleavage of skeletal TnT
generates two different fragments, both binding to Tm. The T1
segment corresponds to the N-terminal region and comprises the
hypervariable and central regions (Potter et al., 1995; Oliveira
et al., 2000; Gollapudi et al., 2013). The hypervariable region
plays a regulatory role in the Tm-binding affinity of TnT site
1 (Amarasinghe and Jin, 2015). The central region is highly
conserved across species, playing a key role in anchoring the
Tn complex to the thin filament through strong interaction
with Tm and performing multiple functions (Heeley et al.,
1987; Lehrer and Geeves, 1998; Palm et al., 2001; Regnier
et al., 2002; Tobacman et al., 2002; Hinkle and Tobacman,
2003). The C-terminal T2 region interacts with TnC, TnI,
actin and a second Tm binding site (Perry, 1998; Jin and
Chong, 2010). In vitro studies have reported that TnT presents
several phosphorylation sites, including Thr197, Ser201, Thr206,
and Thr287 (mouse sequence) (Noland et al., 1989; Wei and
Jin, 2011). Upon phosphorylation, these regions seem to be
negative regulators of maximal force and Ca2+ sensitivity. In
particular, Thr206 phosphorylation is critical for the functional
properties of the thin filament (Sumandea et al., 2003, 2009).
Although phosphorylation seems to play an important regulatory
role in cTnT, the same pattern of phosphorylation was not
observed in vivo. Of note, cTnT from mouse, rat and human
tissues appears to be either monophosphorylated in Ser2 or
unphosphorylated (Perry, 1998; Sancho Solis et al., 2008; Zhang
et al., 2011; Streng et al., 2013). One reasonable explanation for
these discrepant phosphorylation results is the high degree of N-
terminal region conservation compared to other phosphorylation
sites. In addition, the tridimensional arrangement of cTnT
in the thin filament could occlude the other phosphorylation
sites. Indeed, the specific role of Ser2 phosphorylation remains
unclear (Solaro and Kobayashi, 2011). Monasky and coworkers
revealed in a mouse model that the p21 kinase regulates cTnT
phosphorylation in global myocardial ischemia and reperfusion
injury. This result suggests that cTnT phosphorylation regulates
cardiac homeostasis (Monasky et al., 2012; Streng et al., 2013).
Inherited cardiomyopathies caused by cTnT mutations
account for ∼15–30% of all HCM reports. In this context, the
two cTnT-Tm anchoring regions are particularly interesting,
harboring the vast majority of mutations observed so far (Willott
et al., 2010; Figure 3). Once again, we would like to stress that the
maintenance of key intermolecular interactions in this complex
system is particularly important for the homeostasis of the thin
filament function. Thierfelder and coauthors reported the first
cTnT variations associated with HCM (Thierfelder et al., 1994).
cTnT mutations spread in an autosomal dominant manner and
appear to develop a malignant effect with a high incidence of
sudden death (Watkins et al., 1995). Several mutations increase
the Ca2+ sensitivity of force development and the force-pCa
relation, e.g., I79N, R92Q, R92L, R92W, R94L, and A104V.
However, the maximum force generation, ATPase activity and
Ca2+ cooperativity are maintained. On the other hand, R278C
decreases the Ca2+ cooperativity of force generation in skinned
fibers, in addition to the Ca2+-sensitizing effect (Morimoto
et al., 1998, 1999; Morimoto, 2007). These defects illustrate
that cTnT mutations may alter not only the Ca2+ affinity for
the myofilament but also intermolecular contacts. Mutations in
position 92 show different effects on the folding of the cTnT tail
domain (Hinkle and Tobacman, 2003). Additionally, interactions
of R92Q, R92W, R92L, and R94L with Tm-dependent functions
were reported to be impaired (Palm et al., 2001). An interesting
atomistic model has been proposed to identify how these
mutations affect allosteric modulations through the thin filament
(Manning et al., 2012). More interesting, R92L, R92W, and R94L
are still able to induce the muscle generation of force in a Ca2+-
dependent manner, even under an acidic pH. The resistance to
pH also suggests a role in the poor prognosis of HCM (Harada
and Potter, 2004). A contraction event at low pH (e.g., ischemia)
would decrease the intracellular levels of ATP, causing an up-
regulation of the cytokines involved in the activation of apoptotic
pathways (Morimoto et al., 1998). Structurally, these mutations
promote an increase in cTnT helical stability, suggesting a more
rigid structure (Palm et al., 2001). Moreover, the measure of Tm
affinity decreased in all cTnT mutants, strongly suggesting that
the supposed disordered Tm anchoring region plays a role in
Tm-cTnT intermolecular contacts (Palm et al., 2001; Manning
et al., 2012). cTnT mutations tend to be clustered in a conserved
region comprising residues 92 (R92Q, R92L, R92W) and 160–
163 (D160E, E163R, and E163K). Positions 160–163 are located
within the conserved, highly charged region (158-RREEEENRR-
166) and due to their flexibility are believed to play an important
role in the regulation of the thin filament. An interesting study
coupling in vitro and in vivo studies revealed that this region
is exposed to the solvent. Mutations in this cluster alter critical
electrostatic interactions for proper allosteric communication
that leads to the transition from the blocked to the closed
state (Moore et al., 2013, 2014). When expressed in mouse
hearts, structural changes induced by R92Q were able to increase
ATP consumption in the intact beating heart. However, using
activating Ca2+ concentrations, R92Q decreases the energy-
driven force, leading to a failure in the contractile performance
(Tian and Ingwall, 1996; Chandra et al., 2001; Javadpour et al.,
2003; Schwartz and Mercadier, 2003; Jimenez and Tardiff, 2011).
This evidence suggests that this mutation is able to disrupt the
myofilament Ca2+ sensibility probably due to impaired Tm-cTnT
interactions (Takahashi-Yanaga et al., 2001b).
Another arginine replacement was reported in position 278
located on the C-terminal end of cTnT (Yanaga et al., 1999).
When reconstituted in rabbit cardiac myofibrils (Sirenko et al.,
2006) or skinned cardiac muscle fibers (Yanaga et al., 1999),
R278C shows an increase in the Ca2+ sensitivity of ATPase
activity; however, the maximum force cooperativity decreases.
Moreover, R278C is able to disorder the α-helical structure of
the wt cTn in addition to modifying the interface between the
cTn core and the rest of the thin filament (Sirenko et al., 2006).
In transgenic mice carrying R278C, the effect of Ca2+ sensitivity
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was not observed; however, the decrease in the maximal force
corroborates the results of previous studies (Hernandez et al.,
2005). cTnT-R278C impairs cardiac relaxation and diastolic
function, which may be related not only to alterations in the
cross-bridge cycling and/or detachment but also to alterations
in Ca2+ sensitivities, contributing to the pathogenic effects of
this mutant. Interestingly, Brunet and coworkers proposed a
model to explain the structural and molecular role of both cTnT
R278C and cTnI R145G. These mutations appear to affect the
sliding event, indicating possible molecular explanations for the
observed diastolic dysfunction (Brunet et al., 2014). Additionally,
some cTnT mutations (e.g., R92Q and K280N) appear to
be insensitive to the regulatory role of cTnI phosphorylation
(Messer et al., 2016).
TROPONIN C
Different TnC isoforms are expressed in human cardiac/slow
skeletal and fast skeletal muscle cells and are encoded by the
TNNC1 and TNNC2 genes, respectively. cTnC presents ∼70%
identity with the skeletal form. During evolution, the three-
dimensional arrangements were widely conserved between both
isoforms but diverged in their ability to bind Ca2+. cTnC
plays an important role in the regulation of muscle contraction
and relaxation due to the binding of Ca2+. TnC belongs to
the superfamily of EF-hand proteins, comprising two globular
domains connected by a central alpha helix (Herzberg and
James, 1985; Sundaralingam et al., 1985). A canonical EF-hand
motif is composed of two alpha-helices surrounding a loop
segment that is responsible for divalent ion coordination. EF-
loops are flexible and enriched with negatively charged amino
acids, such as aspartic and glutamic acid. The basic coordination
geometry comprises a pentagonal bipyramidal arrangement, in
which seven chelating groups are responsible for ion connection.
Importantly, this is the same arrangement observed in solution.
The six chelating residues are classified first based on the
linear position and second by aligning the geometric axis of a
pentagonal bipyramid: 1 (+X), 3 (+Y), 5 (+Z), 7 (−Y), 9 (−X),
and 12 (−Z). Of note, the carboxylate group in the side chain
of the residue at the twelfth position (glutamic acid in ∼92%
of cases) provides a bidentate bond (Gifford et al., 2007). The
C-terminal domain of TnC, also called the structural domain,
is essential for the interaction with thin filaments and is able
to bind Ca2+ with high affinity (∼107 M−1) and competitively
bind Mg2+ (∼103 M−1). Although the cNTnC has two Ca2+
binding sites, site I is inactive due to several loop substitutions
that impair Ca2+ coordination, for example, the inclusion of
hydrophobic residues instead of charged residues in the +X and
+Y positions (Gillis et al., 2007). Thus, contraction starts when
Ca2+ binds to site II, conferring upon the N-terminal domain a
regulatory role (Kobayashi and Solaro, 2005). It is known that
the amount of hydrophobic exposure driven by Ca2+ binding
at the N-terminal domain directly influences the strength of
the Ca2+ signal transmitted through the thin filament (Li et al.,
1999). Under physiological conditions, the binding of Ca2+ at
the N-terminal domain is not sufficient to trigger an open cTnC
state. To achieve an active state, two factors are important: (i)
the binding of Ca2+ at site II and (ii) the interaction between
cTnC and cTnI leading to changes in the number of hydrophobic
patches and to the further stabilization of the open active state.
Both factors are essential for contraction.
cTnC mutations associated with the HCM phenotype
(Figure 3) alter two key mechanisms: the affinity for Ca2+ and
the cTnC cellular partner interactions. Currently, the frequency
of cTnC mutations is comparable to that of other targets,
such as α-Tm and actin (Van Driest et al., 2003). The first
described mutation was reported in a 60-year-old male patient
presenting clinical signs of atrial fibrillation and hypertrophy of
the left ventricle walls (Hoffmann et al., 2001). DNA sequencing
revealed a T-to-A substitution at position 112, hence causing a
leucine-to-glutamine exchange at amino acid 29. This mutation
corresponds to the +X position within inactive site I; however,
L29Q can change the Ca2+ sensitivity (Schmidtmann et al.,
2005; Dweck et al., 2008; Liang et al., 2008; Neulen et al.,
2009; Gollapudi and Chandra, 2012). Although divergent data
exist with regard to whether this mutant leads to a decrease
or increase in the cTnC Ca2+ affinity, the presence of Gln at
position 29 may destabilize the A helix (Liang et al., 2008),
thereby disturbing the Ca2+ binding properties at site II.
Additionally, the A helix plays a role in the opening of cNTnC,
an important stepwise mechanism for contraction (Li et al.,
2000). Compared to wt, the L29Q mutant was insensitive to
the interaction with a cTnI N-terminal region regardless of the
presence of cTnI phosphorylation, suggesting desensitization to
important biological contacts (Baryshnikova et al., 2008a; Li et al.,
2013; Messer and Marston, 2014). Furthermore, using nuclear
magnetic resonance tomeasure theN-terminal domain backbone
dynamics of salmonid orthologous cTnC (ScNTnC), site I was
more flexible than site II. ScNTnC displays a Gln at position
29 and results in a more open structure and a larger solvent-
accessible area (Blumenschein et al., 2004). Finally, structural
and functional assays revealed that the overall structure of L29Q
has not changed, however small conformational dynamics were
observed (Robertson et al., 2015). Based on the physiological
mechanism of cTnC, these features help to understand the
alterations in Ca2+ sensibility and protein-protein interactions.
Another mutation located within site I was reported in a 5-year-
old boy (Parvatiyar et al., 2012). The alanine exchange at position
31 to a serine was reported as a de novomutation and introduces
a polar amino acid into the Y position. This alanine is a highly
conserved residue among different species, and the impact of
this mutation results in severe alterations in the Ca2+ binding
properties. Functional studies have revealed that A31S increases
the Ca2+ affinity in isolated cTnC or in thin filaments. Moreover,
A31S increases actomyosin ATPase activation and enhances thin
filament activation (Parvatiyar et al., 2012). Mutagenesis and
three-dimensional visualization showed that a hydroxyl group
promotes an additional hydrogen bond with D33, thus providing
rigidity to site I in a similar conformation as that for the skeletal
TnC after Ca2+ binding (Parvatiyar et al., 2012).
Four other mutations associated with HCM phenotype were
described, i.e., A8V, C84Y, E134D, and D145E (Landstrom et al.,
2008). Functional studies have revealed that the E134D mutation
Frontiers in Physiology | www.frontiersin.org 10 September 2016 | Volume 7 | Article 429
Marques and de Oliveira Structural Perspectives in Hypertrophic Cardiomyopathy
has very similar Ca2+-binding affinities and force development
as those of the wt (Pinto et al., 2009). Thus, this variant does
not appear to be pathogenic, at least regarding these studied
parameters. However, C84Y showed an increase in the Ca2+
sensitivity of force development and force recovery, in addition
a sensitized ATPase activity of reconstituted myofilaments (Pinto
et al., 2009). The A8V mutant is located in the N-helix, a region
that plays an important role in the Ca2+ affinity of the N-
terminal domain and interacts with helices A and D through
hydrophobic and electrostatic interactions in the presence of
Ca2+ (Herzberg and James, 1988; Gagné et al., 1995; Slupsky
and Sykes, 1995; Houdusse et al., 1997; Strynadka et al., 1997).
This N-helix mutant showed an increased Ca2+ sensitivity of
force development and force recovery but did not appear to affect
the intrinsic Ca2+ binding property (Landstrom et al., 2008).
However, in the presence of the thin filament, A8V revealed an
increase in the Ca2+ sensitivity of the reconstituted myofilament
(Pinto et al., 2009, 2011a). Accordingly, A8V significantly
increased the sensitivity of actomyosin ATPase regardless of
the phosphorylation status of cTnI. In addition, A8V mutation
led to a slower rate of Ca2+ dissociation in the presence or
absence of phosphorylated TnI (Albury et al., 2012). Thus, it is
reasonable that A8V affects cTnI-cTnC interactions or promotes
an imbalance in cross-bridges that may further increase the Ca2+
affinity. Martins and coworkers reported the first animal model
carrying the A8V heterozygous mutation. In agreement with in
vitro studies, A8V revealed a Ca2+ sensitizer effect in mice. A8V
mice developed right ventricular hypertrophy, hyperdynamic
systolic function, atrial enlargement, fibrosis, and myofibrillar
disarray, consistent with an HCM phenotype. Additionally,
Ca2+ mishandling contributed to an altered contraction, leading
to a severe heart remodeling. A reduction of phosphorylated
cTnI (cTnI-P) levels was observed in A8V heart samples. This
finding agrees with recent investigations suggesting that in
humans, sarcomeric mutations have decreased the levels of cTnI-
P (Sequeira et al., 2013; Martins et al., 2015). Finally, a molecular
mechanism based on altered interactions between cTnC and cTnI
has been proposed as the primary source of functional changes
observed for myofilaments carrying the A8Vmutation (Zot et al.,
2016). The D145E mutant also revealed Ca2+ sensitizer effects
in the myofilament. Interestingly, D145E is located at the +Z
position within site IV and is the only mutation presented in the
C-terminal domain that displays Ca2+-binding disarray. Steady-
state fluorescence studies using IAANS revealed that the N-
domain of D145E has a higher affinity for Ca2+ than does the
wt in an isolated system or within the troponin complex (Pinto
et al., 2011a). However, the ability to bind Ca2+ in the C-terminal
domain appears to be drastically reduced (Swindle and Tikunova,
2010).
TROPOMYOSIN
Tm constitutes a diverse family of proteins that are ubiquitously
expressed in eukaryotic cells. Four genes (TPM1, 2, 3, and 4)
integrate this multigene family in vertebrates, and each gene can
produce different splicing isoforms in specific tissues. Of note,
α-Tm is the predominant isoform expressed in the heart and
comprises 284 residues. Gene shuﬄing leads to the expression
of at least 40 Tm isoforms, and this multiplicity seems to
play a pivotal role in cell maintenance (Gunning et al., 2005).
Accordingly, using transgenic mice overexpressing β-Tm in the
heart, Palmiter and coauthors showed that the replacement of
α-Tm with β-Tm alters its structural and functional properties,
leading to abnormal thin filament activation (Palmiter et al.,
1996). Moreover, α-Tm plays a central role in regulating actin-
myosin interactions that is indirectly controlled by the levels of
Ca2+. A three-state model (blocked, closed, and open) has been
proposed in an attempt to explain this dynamic and allosteric
actomyosin regulation. Under resting conditions and low Ca2+
levels, the regulatory site of TnC is empty, characterizing the
blocked state. Additionally, the interaction between actin and
TnI is stabilized, and Tm locks actin-myosin interactions. The
closed state is characterized by the binding of Ca2+ to the
regulatory domain of cTnC and the exposure of a hydrophobic
patch that further interacts with the C-terminal domain of
cTnI. Moreover, the inhibitory peptide of cTnI moves away
from actin. This transition state is characterized by the partial
exposure of the myosin binding sites triggered by an azimuthal
motion of Tm over the actin filament, generating weakly bound
cross-bridges (Geeves and Lehrer, 1994; Lehrer, 1994). Finally,
the open state is achieved in the presence of myosin heads,
leading to the attachment of strong cross-bridges, allowing Tm
to shift further on the actin filament and potentiate thin filament
activation. Altogether, a tightly allosteric regulation through
dynamic interactions is required to accommodate Tm along with
the thin filament (Gordon et al., 2000; Kobayashi and Solaro,
2005; Solaro, 2010).
The human α-Tm is a coiled-coil dimer rolling over seven
continuously actin monomers that provides actin filament
support and the anchoring of the troponin complex. The α-
Tm primary sequence consists of a short range of seven-residue
pseudo repeats called a “heptad.” These residues are categorized
as the form “a-b-c-d-e-f-g,” in which the a and d positions
are often occupied by non-polar residues. These residues are
responsible for the coiled-coil interface of the interaction and
are essential for α-Tm stability. In contrast, the e and g positions
present hydrophilic amino acids responsible for inter-helical salt
bridges. The b, c, and f positions are exposed to the surface
of the coiled-coil domain and are mainly filled with negatively
charged residues that interact with the positively charged groove
of F-actin (Wolska and Wieczorek, 2003; Barua, 2013; von der
Ecken et al., 2015).
Similar to other sarcomeric genes, TPM gene mutations are
also correlated with hypertrophic and dilated cardiomyopathy
phenotypes (Thierfelder et al., 1994; Olson et al., 2001) but
occur at very low frequencies (around less than 1%), as reported
by large-scale studies (Richard et al., 2003; Van Driest et al.,
2003). The incorporation of specific α-Tm mutants (A63V,
K70T, D175N, and E180G) into adult cardiomyocytes revealed
different isometric force measurements at submaximal Ca2+
concentrations, suggesting that HCM-related α-Tm mutants
would predict clinical severity (Michele et al., 1999). Mutant
transgenic mice were generated to investigate the pathological
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alterations triggered by the α-Tm D175N mutant, resulting
in a severe impairment of heart contractility, relaxation
and increased thin filament activation (Muthuchamy et al.,
1999). Most of the HCM-related mutations in α-Tm increase
thin filament Ca2+ sensitivity of force generation (Redwood
and Robinson, 2013). However, different Ca2+ sensitivity
measurements were obtained for D175N when considering
transfected cardiomyocytes (mutant with a similar behavior
to that of wt) and skinned fibers (higher Ca2+ sensitivity
for the mutant). Interestingly, an evaluation of biopsies from
two patients carrying the HCM-related α-Tm mutant D175N
revealed the in vivo incorporation of the mutation within
the vastus lateralis muscle, resulting in an altered contractile
function (Bottinelli et al., 1998). The mutant and wt forms were
shown to be equally expressed in this biopsies, demonstrating
a negative-dominant profile for α-Tm in human muscle cells
(Bottinelli et al., 1998). Following this study, different studies
using reconstituted thin filaments with a wt/mutant mixture
or Tm heterodimers were conducted with different results
(Lakdawala et al., 2010; Janco et al., 2012). Of note, the in
vitro production of α-Tm heterodimers carrying wt/D175N and
wt/E180G revealed that mutations have little effect on dimer
assembly and actin affinity compared to wt homodimers (wt/wt),
but mutant homodimers have a slightly slower affinity compared
to wt (Janco et al., 2012). More interesting, the D175N mutation
was recently characterized using cardiomyocytes derived from
patient-specific human-induced pluripotent stem cells (hiPSCs),
in which D175N-hiPSCs revealed abnormal Ca2+ transients and
prolonged action potentials compared to hiPSCs carrying the
myosin-binding protein C Q1061X mutation (Ojala et al., 2016).
Recent studies have focused on the biochemical and
biophysical characterization of HCM- and DCM-associated
α-Tm mutations as a strategy to better understand the
primary effects and consequences triggered by mutations
in the long-range communication of the thin filament and
specific phenotypes (Chang et al., 2014; Gupte et al., 2015).
Additionally, the phosphorylation status of α-Tm and its effects
on hypertrophic hearts were recently explored (Schulz et al.,
2012, 2013; Schulz and Wieczorek, 2013). Although α-Tm
phosphorylation dates back to the eighties (Ribolow and Barany,
1977), the protective link to hypertrophic phenotypes is just
now emerging. Transgenic mice carrying the S283A α-Tm
mutation that abrogates the α-Tm phosphorylation site exhibit a
hypertrophic phenotype and increased protein levels and activity
of the Ca2+ ATPase 2a (Serca) but, surprisingly, no changes in
the myofilament Ca2+ sensitivity or the response to β-adrenergic
challenges (Schulz et al., 2012). Accordingly, in a double-
mutant transgenic mouse carrying the HCM-associated α-Tm
mutant E180G together with S283A, the pathogenic phenotype
of hypertrophic hearts was abrogated (Schulz et al., 2013).
Although several studies have had significant contributions,
the impact of α-Tm mutations and phosphorylation on
the mechanism developed by the protein during excitation-
contraction coupling and its correlation with the hypertrophic
phenotype remain speculative. Because this coiled-coil complex
influences thin and thick filament interactions, we believe from
a simplistic viewpoint that alterations in α-Tm would transmit
structural changes by allostery on both sides of these contractile
units. Therefore, further studies should explore the long-term
effects of α-Tm mutations for a clear-cut correlation between the
mutagenic profile and the hypertrophic phenotype.
ALLOSTERIC COMMUNICATION DEFINES
THE HIERARCHY OF FUNCTIONAL AND
PATHOLOGICAL STATES
More than 80% of eukaryotic proteins share in their primary
sequences intrinsically disordered regions (IDRs) flanked by
packed domains. The complexity of these multi-domain
architectures was in the past attributed only to their folded
modules, but recent investigations and emerging techniques in
structural biology have shown the key participation of IDRs
as dynamic elements triggering signaling hierarchy and tuning
protein functionalities. This new “apple of the eyes” has the
potential to dissect hidden molecular mechanisms participating
in physiological and pathological phenotypes. The premise that
function follows structure has been left behind. A particular
example is subunit I of the troponin complex (Hoffman and
Sykes, 2008; Julien et al., 2010). TnI has IDRs with degrees of
conformational flexibility that directly impact biological effects,
mostly by changing the conformation and function of its partner,
the TnC. The degree of disorder in the cTn complex was recently
linked to HCM and DCM-causing mutations. Mutations mostly
cause decrease in the disorder of cTnI and cTnT instead of an
increase (Na et al., 2016). The structure and dynamics of the
N-terminal region of cTnI were also explored, revealing the
multiplicity of structural profiles assumed upon binding to the
cNTnC (Hwang et al., 2014). Additionally, clear evidence of
allostery inward of the troponin complex was revealed using
pathogenic troponin T mutations. A mechanism in which
changes in one protein indirectly affect a third through dynamic
changes in a second protein reflects the allosteric transfer of
information that culminates in pathogenic phenotypes (Williams
et al., 2016). Moreover, the recovery of thin filament sliding speed
of the double mutant cTnI-R145G-cTnT-R278C in comparison
with cTnI-R145G alone provide further evidence of allosteric
transmission within the Tn complex (Brunet et al., 2014). These
allosteric mechanisms may represent an interesting strategy in
future pipelines for therapeutic intervention of cardiomyopathies
based on distant drugable sites inward of Tn subunits or even
in other components of the sarcomere. The binding of different
protein modules, recently characterized as supra-domain units
(Papaleo et al., 2016), with different times, cellular conditions,
and environments provides a newmolecular repertoire for tuning
communication transfer and is just now emerging.
The assembly of macromolecular complexes, such as the thin
and thick filaments involved in muscle contraction, requires a
well-tuned hierarchy of events for proper function. Regardless
of the importance of this molecular motor in triggering human
mobility, power stroke and heartbeat, correct communication
among its individual elements is defined by allostery. Noteworthy
is the fact that the switch-on and -off of this complex machinery
is triggered by the influx and binding of Ca2+ to the C subunit of
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the troponin complex. The linker connecting the TnC structural
and regulatory domains was shown to communicate both
regions in a synergistic way (Grabarek et al., 1986; Moncrieffe
et al., 1999; de Oliveira et al., 2013). The identification and
functional characterization of HCM and DCM mutations in
cTnC (Hoffmann et al., 2001; Landstrom et al., 2008; Willott
et al., 2010) and other sarcomeric proteins (Geisterfer-Lowrance
et al., 1990; Thierfelder et al., 1994; Redwood and Robinson,
2013; Chang et al., 2014), the alterations in Ca2+ sensitivity
of force development and ATPase activity (Pinto et al., 2009,
2011a,b; Parvatiyar et al., 2012), and the appearance of the
disease phenotype point toward a multidirectional change of
allosteric pathways throughout the entire filament. Of note, an
HCM-causing mutant at the Ca2+-binding site IV of cTnC
(D145E) leads to an increased affinity of the Ca2+-binding site
II (Pinto et al., 2009), providing clear evidence for allosteric
communications between both domains. The mechanism under
which this mutation affects a distal region of cTnC is still unclear
but probably altered dynamics at the structural cTnC domain
due to ion impairment at site IV, and communication transfer
through the N-/C- linker might occur (Swindle and Tikunova,
2010). In agreement with this hypothesis, an H/D exchange
analysis of wt cTnC revealed unprotected behavior in residues
linking both domains, suggesting a higher mobility of this
segment (Kowlessur and Tobacman, 2010). A short-term intra
allosteric communication of D145E would impose molecular
recognition changes in cTnC biological partners that ultimately
lead to the HCM phenotype. Extensively dynamic propagation
to cTnI inhibitory regions may also occur through the release of
Ca2+, thus revealing dynamic adjustments throughout the entire
troponin complex (Kowlessur and Tobacman, 2012).
Personalized structural and functional studies of hypertrophic
and dilated cardiomyopathy-related mutants provide a
framework to start assessing the plethora of short- and
long-term allosteric pathways and to unveil the mechanisms
behind their pathogenic effects. For example, the L29Q cTnC
mutation involved in HCM does not drastically affect protein
dynamics but reveals a slight increase in backbone flexibility at
the cTnC regulatory domain (Robertson et al., 2015). Because
intramolecular dynamics do not explain L29Q effects, changes
in the long-term molecular recognition of its biological partners
should justify its pathogenic behavior. Indeed, L29Q abolishes
the effect of force-generation myosin cross-bridges (Robertson
et al., 2015). In the case of A8V, a more open N-terminal domain
conformation was observed compared to the wt in the apo and
holo states, as revealed by paramagnetic relaxation enhancement
(Cordina et al., 2013). In the dilated cardiomyopathy G159D
mutation, no abrupt changes in backbone dynamics were
observed by T1 and T2 relaxation rates. However, a weak
anchoring of cTnI to this mutant was revealed by NMR chemical
shifts and NOE connectivity patterns (Baryshnikova et al.,
2008b), providing insight to explain the disease phenotype.
This weaker interaction probably results in increased levels of
acto-myosin inhibition and reduced ATPase activity (Mirza et al.,
2005). Changes in allosteric communication are not exclusively
related to disease-associated mutations but rather are also related
to post-translational modifications. The N-terminal region of
cTnI is sensitive to phosphorylation by PKA (Chandra et al.,
1997) at specific serine residues (Ser23/24), which results in
changes in the Ca2+ sensitivity of the cNTnC through cTnI
itself and through interactions with cTnT (Wattanapermpool
et al., 1995; Schmidtmann et al., 2002). The kinase promiscuity
of Ser23/24 in cTnI (Solaro et al., 2013) reveals the convergence
of multiple signaling pathways and the crucial role of cTnI as a
central hub for communication transfer. The phosphorylation
of cTnI by PKA enhances the rate of closing the cTnC N-
terminal domain induced by Ca2+ dissociation compared to
non-phosphorylated TnI, but this enhancement is abolished by
both L29Q and G159D mutations (Dong et al., 2008), revealing
a complex scenario of allosteric modulators. Regardless of
intra- or inter allosteric changes triggered by cardiomyopathy
mutations, the communication within this complex machinery is
a highway containing several aﬄuents, and an understanding of
the short- and long-term dynamic maps would help to decipher
the heterogeneous phenotype of cardiomyopathies and pinpoint
new platforms for drug discovery.
STRUCTURAL BIOLOGY EFFORTS AND
TREATMENT IN THE SARCOMERE
Structural biology is an exciting field that focuses on
the elucidation of the three-dimensional architecture of
biomolecules. This field dates back to the fifties with the
breakthrough DNA model of Watson and Crick (Watson and
Crick, 1953). The thin filament structure was first reported by
Ebashi (1972). Groundwork using X-ray diffraction and electron
microscopy provided the basis for Tn and Tm regulation in thin
filaments (Huxley, 1972; Spudich et al., 1972; Parry and Squire,
1973). At the end of the nineties, the location of tropomyosin
on F-actin filaments was determined from negatively stained
electron micrographs (Lehman et al., 2000). Because Tn is
repeated every seventh actin molecules, the density distribution
of Tn is spread out during EM reconstructions. Thus, through
a shorter Tn symmetry in thin filaments using an engineered
internal deletion mutant of Tm, in which three of the seven
actin-binding pseudo repeats were depleted, the Tn complex
could be visualized by EM for three-dimensional reconstruction
(Lehman et al., 2001). Considering Tn alone, some valuable
efforts were made using X-ray diffraction (Takeda et al., 2003;
Vinogradova et al., 2005), but because of limitations due to the
flexibility and hydrophobicity of some terminal segments of TnI
and TnT molecules, the entire Tn complex (∼80 kD) could not
be fully crystallized. Of note, half of the inhibitory segment of TnI
(TnI127–148) is not observed in current crystal structures (PDB
codes 1J1E and 4Y99), limiting the structural and functional
characterization of this inhibitory segment for peptide assays
(Lindhout and Sykes, 2003). Crystal structures of different
constituents of the thin filament to align EM images were used
to better represent this molecular assembly (Pirani et al., 2006;
Poole et al., 2006). A single-particle analysis can help to better
understand the structural complexity of the thin filament (Paul
et al., 2009; Yang et al., 2014). Of note, cryo-EM structures were
used to explain possible mechanisms during transition from
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the close to the open state of the actin:tropomyosin complex
(Sousa et al., 2013). The correct orientation of Tn in the acto-Tm
complex is a matter of debate. However, a recent application
of single-particle procedures for molecular reconstructions has
revealed the orientation of troponin on native relaxed cardiac
muscle at a resolution of 25 Å (Yang et al., 2014). Regarding the
question of thin and thick filament interactions, a recent electron
cryomicroscopy structure provided a greater understanding
of the human actomyosin complex at 3.9 Å, in which the F-
actin myosin interface is stabilized by hydrophobic interactions
throughout most of the interface (von der Ecken et al., 2016). The
use of crystal structure comparisons and combined alignments
provided structural details on actin-myosin conformational
changes that discriminated the weak and strong myosin-binding
states in F-actin. The authors declared that the lack information
among states is due to the absence of intermediate conformations
of myosin bound to F-actin, making interpretations of whether
Pi is released before or after the powerstroke inconclusive (von
der Ecken et al., 2015, 2016).
In the case of NMR, one tremendous advantage is the
possibility to assess protein dynamics. Using 1H NMR spectra
as a function of temperature, the groundwork from Wagner and
Wüthrich revealed that aromatic side chains located inside a
hydrophobic protein core may have rotational motions (Wagner
and Wüthrich, 1978). The broad research community now
accepts that molecular function is intimately related to dynamics.
Several biological processes require dynamic transitional states,
such as enzyme catalysis, in which key residues should be
correctly positioned to coordinate the substrate at the active
site, and ligand binding, which requires the entry of small
molecules or ions to non-exposed clefts. Furthermore, in
molecular recognition events and allostery, protein dynamics
act as “short-term memories” to pass information. In addition,
intra-motions and intermolecular motions that are transmitted
to distal sites, also participate in the transfer of these
“memories” for proper protein operation. NMR provides a
unique opportunity to assess different biological motions ranging
from picoseconds to seconds. For example, the use of the
T1 and T2 relaxation rates is suitable for measuring fast
dynamics on the order of a pico- to nanosecond timescale,
while Carr-Purcell-Meiboom-Gill (CPMG) relaxation dispersion
experiments are sensitive to millisecond motions (Carr and
Purcell, 1954). Notwithstanding, CEST and DEST experiments
are pushing toward the quantification of slow chemical exchange
(Vallurupalli et al., 2012). Regardless of the size limitation for
NMR studies, several of these experiments have been used
to not only provide high-resolution NMR models but also to
characterize the dynamics of cardiomyopathy-related mutants
of isolated sarcomeric proteins. These data provide a unique
strategy to start unveiling the communication transfer and
allostery within the sarcomere.
NMR spectroscopy is also a very powerful technique for small-
molecule screenings (Valente et al., 2006). Regarding this issue
and focusing on sarcomeric proteins, TnC, the Ca2+ sensor of
the sarcomere, has gained much attention. In addition to playing
a crucial role triggering muscle contraction, TnC has become a
feasible target for drug discovery because it is easily handled,
and upon Ca2+ binding, TnC exposes “drugable” hydrophobic
sites for small-molecule tests. The group of Dr. Brian Sykes
has greatly contributed to identifying small-molecule candidates
that bind to TnC (Hwang and Sykes, 2015). Both synthetic
and natural molecules were studied by NMR and were shown
to bind the regulatory and structural domains of TnC, e.g.,
trifluoperazine (Kleerekoper et al., 1998), bepridil (Li et al., 2000;
Wang et al., 2002), levosimendan (Robertson et al., 2008), a
W7 inhibitor (Hoffman et al., 2005; Hoffman and Sykes, 2009),
EMD57033 (Wang et al., 2001), the flavonoid epigallocatechin
gallate (Robertson et al., 2009), and the polyphenol resveratrol
(Pineda-Sanabria et al., 2011). Most of these TnC binders act
as Ca2+ sensitizers and bind to the TnC-TnI148–163 interface.
Recently, a TnC-TnIchimera containing the switch segment of
TnI (TnI148–163) was validated as a tool for producing isotopically
labeled Tn peptides for NMR structural and drug-screening
tests (Pineda-Sanabria et al., 2014). NMR spectroscopy was
also used to characterize and validate a bifunctional rhodamine
probe attached to cysteines of the skeletal TnC as a strategy
for the in situ measurement of the orientation and motions
of TnC (Mercier et al., 2003; Julien et al., 2008). Finally, the
rational design of Ca2+-sensitizing mutants in the regulatory
domain of cTnC is a good strategy for pinpointing key residues
that would mimic the characteristic effects of cardiomyopathies
and also to understand the properties of ion coordination and
their structure-activity relationships (Tikunova and Davis, 2004;
Parvatiyar et al., 2010).
While structural biology provides a mean to the
understanding of how biomolecules behave in solution and
has been used to uncover important molecular mechanisms
within the sarcomere, cellular therapy, specifically the use of
human pluripotent stem cell (hiPSCs), has the potential to
reproduce physiological and pathological phenotypes in vitro
(Han et al., 2014; Matsa et al., 2016). Viral transduction of
combined transcription factors was able to reprogram fibroblats
to pluripotent stem cells, opening up a tremendous advance
for personalized medicine care (Takahashi and Yamanaka,
2006). The use of patient-specific cells for reprogramming
technologies may work as platforms for the generation of a
plethora of new differentiated cells, oriented drug discovery,
toxicological studies, and new research-based investigations that
mimic disease (Matsa et al., 2014; Guo et al., 2015). In HCM, for
example, hiPSC-derived cardiomyocytes revealed hypertrophy,
disorganization of the sarcomere and increased expression of
genes, e.g., NFAT and calcineurin. More interesting, the use of
calcineurin inhibitors have shown to reduce the hypertrophic
phenotype (Lan et al., 2013).
SIGNALING IN HYPERTROPHIC
CARDIOMYOPATHY
Adult cardiomyocytes are differentiated and complex cells
playing an unambiguous role in cardiac excitation-contraction
coupling. This is achieved through a fine-tuned communication
signaling of hundreds of molecules organized in weakly and
tightly bound molecular assemblies, including cytosolic and
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transmembrane proteins, ion channels, transcriptional factors,
adaptors, and second messengers (Figure 4). Unfortunately,
this fundamental phenomenon is sometimes challenged by a
repertoire of intrinsic and extrinsic insults or by the effects of
sarcomeric mutations, the latter being the most common but not
exclusive cause of cardiomyopathies. Due to disease complexity,
the discussion of signaling changes will focus on HCM, where
cardiac dysfunction is mainly credited to heart mass increase
FIGURE 4 | Signaling in hypertrophic cardiomyopathy. Schematic representation of the signaling pathways involved in hypertrophic cardiomyopathy. Green, red
and yellow arrows represent promoting activity, inhibitory activity and signaling through Ca2+, respectively. “P” in yellow spheres and “Ub” in red spheres mean
phosphorylation and ubiquitination. Molecules with abbreviated names are as follows: Cito C, cytochrome C; Casp, cysteine-aspartic acid protease; Apaf, apoptotic
protease activating factor; NFAT, nuclear factor of activated T cells; BNP, brain natriuretic peptide; β-MHC, β-myosin heavy chain; CaM, calmodulin; MLP, muscle LIM
protein; T-cap, telethonin; GSK3β, glycogen synthase kinase 3 beta; PDK, 3-phosphoinositide dependent protein kinase 1; PI3K, phosphoinositide 3-kinase; FasR,
Fas receptor; TNFα, tumor necrosis factor α; GPCR, G protein-coupled receptor; β-AR, β-adrenergic; AngII, angiotensin II; ET-1, endothelin; AC, adenylyl cyclase;
PKA, protein kinase A; PLC, phospholipase C; DAG, diacylglycerol; IP3, inositol 3-phosphate; IP3R, inositol 3-phosphate receptor; SR, sarcoplasmic reticulum; Tn,
troponin complex; PLB, phospholamban; Serca, sarco/endoplasmic reticulum Ca2+-ATPase; RyR, ryanodine receptor; and ECM, extracellular matrix. LoF and GoF
represent the loss-of-function or gain-of-function phenotype for p53.
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(hypertrophy), interventricular septal thickening, and fibrosis.
The molecular events encompassing the HCM phenotype are
increased protein synthesis, activation of genes expressed during
embryogenesis, shifts in myosin isoforms, altered metabolism,
and altered organization of the sarcomeric architecture.
Regardless of the sarcomeric repertoire of mutations causing
HCM and heart tolerability tomechanical stretch upon heartbeat,
the pathways discriminating physiological and pathological
mechanosensitivities remain scarce. The correct tuning of
biomechanical stress and how molecules sense and trigger
hypertrophy is a matter of debate, but proteins located
at the Z disc and at the costamere complex may play a
role in this mechanotransduction process. The Z disc is
responsible for transferring the tension between the sarcomeres
through the interaction between titin and α-actinin (Luther
and Squire, 2002). Other proteins were also identified in
this environment, e.g., the muscle LIM protein (MLP) and
telethonin (T-cap), in which mutations were already related
to some cardiac diseases, including dilated cardiomyopathy
(Arber et al., 1997). Costameres are complex protein assemblies
connecting the sarcomere to the extracellular matrix and,
together with the Z disc, act as a central station for
sensing mechanostress and transmit information to alter
contractile properties and transcriptional regulation to avoid
heart failure. The mechanotransduction signaling triggered
by these different elements aims to decrease blood volume,
add sarcomeres to increase contractile capacity and change
metabolism to favor energy production. Several lines of evidence
link the mechanical signaling response to hypertrophic events,
but for more in-depth information, please refer to more
specialized literature (Sadoshima and Izumo, 1997 and references
therein).
Heart hypertrophy is a compensatory event that is not
exclusively related to pathology but rather is also related
to the adaptation of the heart to altered contractility and
biomechanical stress. Concentric hypertrophy mainly occurs due
to pressure overload and is characterized by cardiomyocytes
growing laterally with the parallel addition of sarcomeres. From
the other side, excentric hypertrophy is due to volume overload,
leading to longitudinal cellular growth and the “in-line” addition
of sarcomeres (Dorn et al., 2003). Concentric hypertrophy
in HCM is related to changes in cardiomyocyte alignment,
while excentric hypertrophy is related to advanced HCM
(Seidman and Seidman, 2001). One of the signaling pathways
tuning the physiological (adaptation) or pathological response
to hypertrophy is the phosphoinositide 3-kinase (PI3K)/serine-
threonine kinase (Akt) cascade. Depending on the duration of
Akt activation, different cellular responses take place, as observed
from mice carrying ubiquitously activated Akt. The chronic
activation of this kinase results in different phenotypes, ranging
from moderate cardiac hypertrophy to massive cardiac dilation
and sudden death (Matsui et al., 2002). In addition, Akt inhibits
the downstream kinase glycogen synthase kinase 3 beta (GSK-3β)
through phosphorylation. Once in the unphosphorylated state,
active GSK-3β negatively regulates heart size from pathological
insults (Haq et al., 2000; Michael et al., 2004). Transgenic mice
expressing a TnT mutation involved in familiar HCM revealed
that Akt activation and GSK-3β inactivation impact cardiac size
and disease phenotype (Luckey et al., 2009).
Another important signaling triggered by pathological insults
is the G-protein-coupled receptor (GPCR). These receptors
are activated by factors released upon increased pressure or
mechanical stretch, such as angiotensin II and endothelin (ET1),
and play a role in hypertrophic responses. Additionally, GPCR-
dependent PLCβ activation can lead to Ca2+ eﬄux from the
sarcoplasmic reticulum and the activation of calmodulin. This
downstream signaling activates the serine/threonine phosphatase
calcineurin that dephosphorylates the nuclear factor of activated
T cells (NFAT). Thus, NFAT translocates to the nucleus
and reactivates the fetal gene program, which includes the
expression of the brain natriuretic peptide (BNP), α-skeletal
actin and β-myosin heavy chain (β-MHC) (Molkentin et al.,
1998). The reactivation of cardiac fetal genes normally occurs
in cardiomyopathies (Kuwahara et al., 2003), and these
genes have been shown to be up-regulated in calcineurin
transgenic mice (Molkentin et al., 1998), suggesting hypertrophic
signaling as an alternative to overcome pathological effects.
The increase in the β-MHC isoform and the concomitant
decrease in the α-MHC isoform are great biomarkers for
early cardiomyopathy (Lowes et al., 1997; Miyata et al.,
2000).
The production and deposit of collagen type I and
III by fibroblasts are other alterations observed in early
cardiomyopathy characterizing fibrosis. Increased deposits may
impair the excitation-contraction coupling, leading to severe
changes in heart contractility (Menon et al., 2009). Hypertrophic
cardiomyopathic hearts expressing gene mutations in α-myosin
heavy chain were shown to increase the expression of TGF-β and
stimulate non-myocyte cells to proliferate and express profibrotic
molecules that ultimately lead to myocyte death, contributing to
diastolic dysfunction in HCM hearts (Teekakirikul et al., 2010).
The energy supply of cardiomyopathic hearts is also altered.
Several changes occur to provide more ATP during the initial
stages of cardiomyopathy, with fatty acid oxidation but shifts
to glucose at advanced stages of the failing heard (Neubauer,
2007).
Several lines of evidence also link the activation of apoptotic
signaling in hypertrophic hearts. An investigation of explanted
failing hearts from transplanted patients with cardiomyopathy
revealed increased levels of cytochrome C associated with the
activation of the pro-apoptotic cysteine-aspartic acid protease
3, caspase-3 (Narula et al., 1999). Apoptotic activation was
also observed in myocytes of transgenic mice overexpressing
the Gs α-subunit coupled with GPC receptors upon the
enhanced activation of β-adrenergic stimulus (Geng et al.,
1999). Accordingly, upon norepinephrine stimulation, adult
rat cardiac myocytes revealed apoptosis via PKA and voltage-
dependent calcium channels (Communal et al., 1998). The
increased mRNA and protein levels of the proinflammatory
cytokine tumor necrosis factor-α (TNFα) in explanted hearts
from dilated cardiomyopathic and ischemic patients and the
TNFα-induced apoptosis in rat cardiomyocytes demonstrate the
clear involvement of this programmed cell death mechanism in
cardiomyopathy (Krown et al., 1996; Torre-Amione et al., 1996).
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Tumor suppressor p53 is also a key cell regulator and responds to
DNA damage, inducing cell cycle arrest, senescence, DNA repair
and apoptosis (de Oliveira et al., 2015). Interestingly, pacing-
induced heart failure in dogs revealed increased protein levels
of p53 with the downregulation of Bcl-2 and the upregulation
of Bax in myocytes, consistent with an apoptotic scenario
(Leri et al., 1998). A recent immunohistochemical study in
HCM patients also linked increased levels of p53 and S100A4
proteins with an increased content of collagen fibers, thus,
the modulation of these targets may ameliorate myocardial
interstitial fibrosis (Qi et al., 2016). With regard to the growing
literature on the involvement of aggregated forms of p53 in
different cancer cells lines and tumor tissues (Levy et al.,
2011; Ano Bom et al., 2012; Lasagna-Reeves et al., 2013;
Silva et al., 2014; Yang-Hartwich et al., 2015) and given that
p53 is marginally stable inside the cell and that aggregation
depends on protein concentration, it is reasonable to argue that
misfolded and aggregated forms of p53 might also occur in other
unrelated diseases. Indeed, increased levels of endogenous p53
have already been reported in control and stressed myocytes,
as well as during p53 overexpression (Miyashita and Reed,
1995; Pierzchalski et al., 1997; Leri et al., 1998). In addition,
the short-lived p53 is targeted to the proteasome system due
to the E3-ubiquitin ligase activity of its negative regulator,
MDM-2. Of note, the decreased proteasome activity reported
in HCM and failing human hearts (Predmore et al., 2010)
supports the hypothesis of misfolded p53 accumulation and the
formation of higher-order oligomers of this tumor suppressor.
Furthermore, transgenic mice expressing a myosin-binding
protein Cmutation that were treated with a proteasome inhibitor
were not able to regress the HCM phenotype but rather slightly
improved cardiac function (Schlossarek et al., 2014). The loss-
of-function and gain-of-function phenotypes of oligomeric and
aggregated p53 and their involvement in the development
of HCM are still matters of speculation and require further
exploration.
CONCLUDING REMARKS
The combination of multidisciplinary expertise in structural
biology, biochemistry, physiology, and cellular biology represent
a sine qua non condition for better understanding the thin/thick
filament interactions and ultimately the muscle contraction
phenomena under normal and pathological conditions. The
impact of mutations and post-translational modifications in
sarcomeric proteins and their effects on the generation of non-
adaptive hypertrophy are clarified from a series of well-designed
studies. Because this review was written by structural biologists,
the contribution that should come from this paper is the
provision of a point-by-point investigation of the short- and
long-term allosteric changes in different pathogenic mutations
on isolated proteins and within the context of their biological
partners. Because HCM presents a heterogeneous profile of
genetic inherence, deciphering the altered motions and dynamic
pathways through personalized mutagenic studies will certainly
provide insight for new drugable sites that would have the
potential for future therapeutics to hopefully ameliorate the
hypertrophic phenotype from a broader range of pathogenic
mutants.
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